Background

Recent work shows that full‑dose psilocybin enhances prefrontal cortical dendritic growth and amygdala‑prefrontal connectivity, mediating fear extinction and long‑term psychosocial gains [1][2]. In contrast, chronic microdosing correlates with insomnia, anxiety, and impaired cognition, suggesting that low, non‑psychedelic exposures fail to engage the neuroplasticity pathways while still perturbing monoamine tone [3]. Animal data confirm hippocampal neurogenesis after psilocybin but do not specify the dose‑response curve for synaptic density changes [4]. This gap raises the possibility that a sub‑psychedelic dose, when paired with an external neuromodulatory boost, could reach the plasticity threshold without triggering the full phenomenology that underlies adverse effects.

Hypothesis

We propose that administering a psilocybin dose producing ~30 % of the typical psychedelic subjective intensity (≈1 mg/70 kg oral) together with concurrent anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex will increase BDNF release and synaptic marker expression in prefrontal‑amygdala circuits to levels comparable to full‑dose therapy, while avoiding the adverse symptom cluster seen with microdosing alone.

Mechanistic Rationale

1. Synergistic priming – tDCS depolarizes pyramidal neurons, lowering the threshold for activity‑dependent BDNF transcription [1]. Psilocybin’s 5‑HT2A agonism enhances intracellular calcium via Gq coupling, further activating CREB‑BDNF pathways. The combined signal should surpass the plasticity threshold that microdosing cannot reach.
2. State‑dependent gating – The brief period of elevated cortical excitability post‑tDCS (≈20‑30 min) creates a window where psilocybin‑induced 5‑HT2A signaling preferentially strengthens synapses active during that window, biasing plasticity toward top‑down prefrontal inputs to the amygdala.
3. Avoiding overload – Full psychedelic doses cause global 5‑HT2A activation leading to perceptual alterations and, in some individuals, anxiety‑like states. By limiting agonist exposure, we reduce the likelihood of off‑target limbic overdrive that underlies microdosing‑related insomnia and anxiety.
4. Homeostatic feedback – Moderate 5‑HT2A activation triggers transient intracellular phosphatase activation that prevents excessive downstream signaling, preserving network stability.

Testable Predictions

• Prediction 1: Combined psilocybin + tDCS will produce a significantly greater increase in peripheral BDNF (ELISA) at 90 min post‑session than either psilocybin low‑dose alone or tDCS alone (p < 0.01, ANOVA).
• Prediction 2: Fluorodeoxyglucose‑PET or synaptic vesicle glycoprotein 2A (SV2A) PET will show a ≥15 % rise in prefrontal cortical binding potential 24 h after combined treatment, comparable to changes reported after full‑dose psilocybin [2], whereas low‑dose psilocybin alone will show <5 % change.
• Prediction 3: Resting‑state EEG will reveal increased frontal theta coherence and reduced amygdala‑high‑gamma power after combined treatment, indicating enhanced top‑down control, while microdosing alone will show increased theta‑beta ratio linked to anxiety.
• Prediction 4: Participants receiving the combined protocol will report lower scores on the Adverse Effects Scale (insomnia, anxiety, poor focus) than those receiving matched‑dose microdosing, with no significant increase in psychotic‑like symptoms (CAPS‑5 change <2 points).

Proposed Experimental Design

A double‑blind, randomized, crossover study (n = 30) with four sessions: (A) low‑dose psilocybin (1 mg/70 kg) + sham tDCS, (B) low‑dose psilocybin + active tDCS (2 mA, 20 min, anodal left DLPFC), (C) placebo + active tDCS, (D) placebo + sham. BDNF sampled at baseline, 30, 60, 90 min. SV2A PET at baseline and 24 h post‑session. EEG recorded 15 min post‑tDCS. Clinical outcomes measured with PCL‑5 and WI‑S at 1 week and 1 month.

If predictions 1‑3 are confirmed and prediction 4 shows no excess adverse effects, the hypothesis would be supported, indicating a viable neuroplasticity‑enhancing protocol that sidesteps the limitations of both microdosing and full‑dose psychedelic therapy. Failure to detect BDNF or synaptic changes, or emergence of adverse effects, would falsify the claim that sub‑psychedelic dosing combined with tDCS can therapeutically engage plasticity mechanisms.

References [1] https://neurosciencenews.com/psilocybin-depression-ssris-27652/ [2] https://journals.sagepub.com/doi/10.1177/20451253251342319 [3] https://www.nccih.nih.gov/health/psilocybin-for-mental-health-and-addiction-what-you-need-to-know [4] https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/education/high-school-bioethics-project/learning-scenarios/ptsd-treatment-psychedelics